Immuno-oncology therapy associated thromboembolic events in metastatic renal cell carcinoma

被引：0

作者：

Alhamdani, Zein ^{[1
,2
]}

Alberto, Matthew ^{[1
]}

Ischia, Joseph ^{[1
]}

机构：

[1] Univ Melbourne, Dept Surg, Austin Hlth, Melbourne, Vic, Australia

[2] Austin Hlth, 145 Studley Rd, Heidelberg, Vic 3084, Australia

来源：

UROLOGY CASE REPORTS | 2023年 / 49卷

关键词：

Immune-oncology; Immunotherapy; Thromboembolic; Pulmonary embolism; IVC thrombus; Metastatic renal cell carcinoma; Case report;

D O I：

10.1016/j.eucr.2023.102420

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The relationship between thromboembolic events (TEs) and immune-oncology (IO) agents in patients with metastatic renal cell carcinoma (mRCC) with inferior-vena-cava (IVC) thrombus has not been explored despite conferring significant morbidity. A late 30s female is diagnosed with mRCC with a level-II IVC thrombus after presenting with back pain. Two weeks post initiation of immunotherapy, she re-presented with bilateral sub-massive pulmonary emboli requiring IVC and pulmonary thrombectomy. This case exposes a potential relationship between mRCC and IVC thrombus with IO agents that creates a critically hypercoagulable state. This issue requires further investigation given the apparent under-reporting of TEs in these patients.

引用

页数：3

共 50 条

[21] Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One
Montironi, Rodolfo
Cimadamore, Alessia
Ohashi, Riuko
Cheng, Liang
Scarpelli, Marina
Lopez-Beltran, Antonio
Moch, Holger
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02): : 331 - 333
[22] Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?
Ursula Vogl
memo - Magazine of European Medical Oncology, 2019, 12 : 339 - 341
[23] Repurposing Radiation Therapy for Immuno-oncology
Tang, J.
Malachowska, B.
Wu, X.
Guha, C.
CLINICAL ONCOLOGY, 2021, 33 (11) : 683 - 693
[24] Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy
Mehra, Ranee
Huang, Huan
Seal, Brian
Tse, Jenny
Shenolikar, Rahul A.
Burudpakdee, Chakkarin
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (08): : 2030 - 2038
[25] First-line treatment of metastatic urothelial carcinoma Update immuno-oncology
Zacharis, A.
Gruellich, C.
UROLOGE, 2020, 59 (07): : 797 - 803
[26] Second-line treatment of metastatic urothelial carcinoma Update immuno-oncology
Zschaebitz, S.
Niegisch, G.
UROLOGE, 2020, 59 (07): : 804 - 809
[27] Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials
Kudo, Masatoshi
LIVER CANCER, 2019, 8 (04) : 221 - 238
[28] Long-term response to immuno-oncology after discontinuation for immuno-related pneumonia in metastatic renal carcinoma: a case report
Stellato, Marco
Foderaro, Simone
Tonini, Giuseppe
Vincenzi, Bruno
Santini, Daniele
ANTI-CANCER DRUGS, 2022, 33 (01) : 105 - 108
[29] First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis
Monteiro, Fernando Sabino M.
Soares, Andrey
Debiasi, Marcio
Schutz, Fabio A.
Maluf, Fernando Cotait
Bastos, Diogo Assed
Sasse, Andre
Cauduro, Carolina G. S.
Mendes, Gabriela Oliveira
Ziegelmann, Patricia K.
Fay, Andre P.
CLINICAL GENITOURINARY CANCER, 2020, 18 (04) : 244 - +
[30] Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).
Navani, Vishal
Ernst, Matthew Scott
Wells, Connor
Yuasa, Takeshi
Takemura, Kosuke
Donskov, Frede
Basappa, Naveen S.
Schmidt, Andrew Lachlan
Pal, Sumanta K.
Meza, Luis A.
Wood, Lori
Ernst, D. Scott
Szabados, Bernadett
McKay, Rana R.
Weickhardt, Andrew James
Suarez, Cristina
Kapoor, Anil
Lee, Jae-Lyun
Choueiri, Toni K.
Heng, Daniel Yick Chin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

← 1 2 3 4 5 →